This overactivation of the immune system is why some therapeutic approaches against COVID-19 focus on pharmaceuticals that can reduce the proinflammatory effects of IL-6, such as tocilizumab and sarilumab, which are inhibitors of the IL-6 receptor and have been shown to be effective in reducing the severity of the course of this disease [51,52,53]. Here, IL6 is linked to COVID-19.